USPTO Examiner BOESEN AGNIESZKA - Art Unit 1671

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18800440RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINEAugust 2024December 2024Allow410NoNo
18738696VACCINE MOLECULESJune 2024June 2025Allow1310NoNo
18668571USE AND TREATMENT OF DI-AMINO ACID REPEAT-CONTAINING PROTEINS ASSOCIATED WITH ALSMay 2024March 2025Allow1000NoNo
18665920Compositions and Methods for Antigen Targeting to CD180May 2024March 2025Allow1010NoNo
18662554METHODS FOR CONTINUOUSLY INACTIVATING A VIRUS DURING MANUFACTURE OF A PROTEINMay 2024April 2025Allow1110NoNo
18648190STABILIZED INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOFApril 2024December 2024Allow700NoNo
18616134RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINEMarch 2024August 2024Allow510NoNo
18612698SARS-COV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USEMarch 2024November 2024Allow810NoNo
18612771MULTIVALENT EPSTEIN-BARR VIRUS-LIKE PARTICLES AND USES THEREOFMarch 2024January 2025Allow1010NoNo
18434265HEPATITIS B ANTIBODIESFebruary 2024January 2025Allow1210NoNo
18403182MULTIVALENT INFLUENZA NANOPARTICLE VACCINESJanuary 2024April 2025Allow1620NoNo
18391486T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOFDecember 2023August 2024Allow810NoNo
18527937Immunogenic Compositions to Treat and Prevent Microbial InfectionsDecember 2023May 2025Allow1711NoNo
18388788T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOFNovember 2023June 2024Allow700NoNo
18493004SUBUNIT VACCINE FOR TREATMENT OR PREVENTION OF A RESPIRATORY TRACT INFECTIONOctober 2023July 2024Allow911NoNo
18492095INDUCE AND ENHANCE IMMUNE RESPONSES USING RECOMBINANT REPLICON SYSTEMSOctober 2023December 2024Abandon1410NoNo
18486459MHC CLASS I ASSOCIATED PEPTIDES FOR PREVENTION AND TREATMENT OF MULTIPLE FLAVI VIRUSOctober 2023November 2024Abandon1310NoNo
18480851METHOD FOR ROBUST CONTROL OF GENE EXPRESSIONOctober 2023January 2025Allow1510NoNo
18463235ROTAVIRUS VACCINESSeptember 2023February 2025Allow1710NoNo
18237718T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOFAugust 2023July 2024Allow1010NoNo
18235464COMPOSITIONS INCLUDING SBI ADJUVANTS AND METHODS OF USE THEREOFAugust 2023February 2025Allow1810NoNo
18346456GENETICALLY ENCODED POLYPEPTIDE FOR AFFINITY CAPTURE AND PURIFICATION OF BIOLOGICSJuly 2023August 2024Allow1310NoNo
18344909INFLUENZA VACCINESJune 2023October 2024Allow1610NoNo
18333591DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYSJune 2023August 2024Allow1410YesNo
18332022MHC CLASS I ASSOCIATED PEPTIDES FOR PREVENTION AND TREATMENT OF MULTIPLE FLAVI VIRUSJune 2023August 2024Allow1510NoNo
18296150UNIVERSAL MAMMALIAN INFLUENZA VACCINEApril 2023April 2025Allow2440YesNo
18295994METHODS FOR COMBINING ADOPTIVE T CELL THERAPY WITH ONCOLYTIC VIRUS ADJUNCT THERAPYApril 2023June 2024Allow1520NoNo
18185891METHODS AND COMPOSITIONS FOR ATTENUATING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSESMarch 2023March 2025Abandon2420NoNo
18179668MARBURGVIRUS CONSENSUS ANTIGENS, NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING SAMEMarch 2023December 2024Allow2120NoNo
18077277MARKER COMBINATIONS FOR DIAGNOSING INFECTIONS AND METHODS OF USE THEREOFDecember 2022April 2025Allow2830NoNo
18052541HENIPAVIRUS VACCINENovember 2022September 2024Allow2210NoNo
17937719RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USEOctober 2022July 2024Allow2110NoNo
17951674VIRUS AND ANTIGEN CONJUGATIONSeptember 2022September 2024Allow2320YesNo
17930065LASSA VIRUS VACCINESeptember 2022June 2024Allow2210NoNo
17851187NON-COVALENT LOADING OF PLANT PICOVIRUS PARTICLESJune 2022November 2024Allow2830NoNo
17750612VACCINE COMPOSITIONS HAVING IMPROVED STABILITY AND IMMUNOGENICITYMay 2022August 2024Allow2710NoNo
17719751METHOS FOR RAPID DETECTION AND IDENTIFICATION OF VIRAL NUCLEIC ACIDSApril 2022May 2025Abandon3721NoNo
17706381VIRAL VACCINES AND METHODS OF FORMING THE SAMEMarch 2022June 2025Allow3810NoNo
17623525Recombinant Herpes Zoster Vaccine Composition and Application ThereofDecember 2021May 2025Allow4010NoNo
17543206OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOFDecember 2021March 2025Allow3910NoNo
17596162Designed Inhibitors of Tight Junction FormationDecember 2021May 2025Abandon4210NoNo
17613331NOROVIRUS-BINDING PEPTIDENovember 2021March 2025Allow4010NoNo
17612208VACCINE SPRAY EQUIPMENTNovember 2021June 2025Allow4310NoNo
17606811A SUBUNIT VACCINE FOR TREATMENT OR PREVENTION OF A RESPIRATORY TRACT INFECTIONOctober 2021July 2024Allow3310NoNo
17438178DENGUE VIRUS VACCINEOctober 2021February 2025Allow4110NoNo
17480073COMPOSITIONS AND VACCINES FOR TREATING AND/OR PREVENTING VIRAL INFECTIONS, AND METHODS OF USING THE SAMESeptember 2021March 2025Allow4110NoNo
17435145PORCINE EPIDEMIC DIARRHEA (PED) VIRUS VACCINE COMPOSITION AND PREPARATION METHOD THEREOFAugust 2021March 2025Allow4210NoNo
17424494Means and Methods for Improving Plant Growth and YieldJuly 2021October 2024Allow3911NoNo
17413331RECOMBINANT MUMPS VIRUS VACCINE EXPRESSING GENOTYPE G FUSION AND HEMAGGLUTININ-NEURAMINIDASE PROTEINSJune 2021May 2025Abandon4710NoNo
17413026HEPATITIS B VIRUS VACCINE AND USES THEREOFJune 2021April 2025Abandon4610NoNo
17413130INTEGRATED PROVIRAL SEQUENCING ASSAYJune 2021August 2024Allow3910NoNo
17327784SARS-COV-2 Antigen Polypeptide, Recombinant Adeno-Associated Virus Expressing the Polypeptide, and Vaccine Containing the VirusMay 2021November 2024Allow4211NoNo
17318719Stabilizing Mutants of Prefusion Sars-Cov-2 (Covid-19) Spike Protein And Improved Yeast Surface Display Engineering Platform For The SameMay 2021February 2025Allow4541YesNo
17240858ENGINEERED CRISPR-CAS SYSTEMS AND METHODS FOR SENSITIVE AND SPECIFIC DIAGNOSTICSApril 2021February 2025Abandon4511NoNo
17288133PEPTIDES FOR INDUCING HETEROSUBTYPIC INFLUENZA T CELL RESPONSESApril 2021November 2024Allow4310NoNo
17236516VIRUS DETECTION SYSTEM, VIRUS DETECTION METHOD, AND VIRUS DETECTION PROGRAMApril 2021December 2024Allow4311NoNo
17276649MUCOADHESIVE LIPIDIC DELIVERY SYSTEMMarch 2021December 2024Abandon4510NoNo
17274891ADENOSOMESMarch 2021June 2025Allow5121YesNo
17194308VIRAL PANDEMIC VACCINEMarch 2021June 2023Abandon2710NoNo
17268314GENETICALLY ENCODED POLYPEPTIDE FOR AFFINITY CAPTURE AND PURIFICATION OF BIOLOGICSFebruary 2021October 2024Allow4411YesNo
17264649T CELL RECEPTOR FOR IDENTIFYING AFP ANTIGENJanuary 2021July 2024Allow4110NoNo
17263606METHOD FOR ENHANCING GENE EXPRESSION USING AAV VECTORJanuary 2021August 2024Allow4310NoNo
15733861COMBINED PROPHYLACTIC AND THERAPEUTIC VACCINESNovember 2020August 2024Allow4421YesNo
17055096BINDING MOIETY FOR CONDITIONAL ACTIVATION OF IMMUNOGLOBULIN MOLECULESNovember 2020April 2025Allow5310NoNo
16604711NOVEL DELIVERY OF LARGE PAYLOADSOctober 2019February 2025Allow6021NoNo
16287559HPV EPITOPES TARGETED BY T CELLS INFILTRATING CERVICAL MALIGNANCIES FOR USE IN VACCINESFebruary 2019February 2020Allow1120YesNo
16025624CONSTRUCTION OF WEST NILE VIRUS AND DENGUE VIRUS CHIMERAS FOR USE IN A LIVE VIRUS VACCINE TO PREVENT DISEASE CAUSED BY WEST NILE VIRUSJuly 2018June 2019Allow1110NoNo
15579150VIRAL CHIMERIC PARTICLE OF POTATO VIRUS X AND USE THEREOF FOR IN VITRO DIAGNOSIS OF SJ�GREN SYNDROMEDecember 2017February 2020Allow2611NoNo
15508670MODIFIED BAT INFLUENZA VIRUSES AND THEIR USESMarch 2017December 2018Allow2111NoNo
15507676ANTI-HEPATITIS C ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOFFebruary 2017May 2019Allow2620YesNo
15501339LIQUID IMMUNITY INDUCTION-PROMOTING COMPOSITION AND VACCINE PHARMACEUTICAL COMPOSITION THAT INCLUDE THROMBOSIS TREATMENT DRUGFebruary 2017June 2019Allow2821NoNo
15079013HCV CORE LIPID BINDING DOMAIN MONOCLONAL ANTIBODIESMarch 2016September 2018Allow3011NoNo
15042436ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USEFebruary 2016July 2017Allow1701YesNo
15040277INFLUENZA VIRUS MUTANTS AND USES THEREFORFebruary 2016November 2017Allow2110NoNo
15040705INFLUENZA VIRUS MUTANTS AND USES THEREFORFebruary 2016November 2017Allow2110NoNo
14900834Infectious laryngotracheitis virus (ILTV) vaccine using recombinant newcastle disease virus vectorDecember 2015March 2019Allow3921NoNo
14945384HEPATITIS B VIRUS PRE-S1 DERIVED SYNTHETIC POLYPEPTIDES AND USES THEREOFNovember 2015March 2019Allow3930YesNo
14926989METHOD OF DIAGNOSING AND TREATING EPSTEIN BARR VIRUS-BASED MYALGIC ENCEPHALOMYELITIS CHRONIC FATIGUE SYNDROME PATIENTSOctober 2015September 2018Allow3521NoNo
14725508ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USEMay 2015November 2016Allow1800NoNo
14454341NOVEL COMPOSITIONS AND USES THEREFORAugust 2014January 2018Allow4131NoNo
14335511IN SITU DETECTION OF EARLY STAGES AND LATE STAGES HPV INFECTIONJuly 2014September 2016Allow2621NoNo
14296095INFLUENZA VIRUS-LIKE PARTICLE (VLP) COMPOSITIONSJune 2014March 2016Allow2120NoNo
14360524HPV Chimaeric ParticleMay 2014May 2017Allow3631YesNo
14131616Vaccine Composition With Aluminium Hydroxide NanoparticlesApril 2014May 2017Allow4131NoNo
14342129NUCLEIC ACID CONSTRUCT COMPRISING NUCLEIC ACID DERIVED FROM GENOME OF HEPATITIS C VIRUS OF GENOTYPE 3aApril 2014June 2016Allow2711NoNo
14175892METHODS OF MODULATING HVEM, BTLA AND CD160 CIS COMPLEX RESPONSE OR SIGNALING ACTIVITY WITH SOLUBLE LIGHT POLYPEPTIDE SEQUENCESFebruary 2014October 2018Allow5750NoNo
14000815MULTIMERIC MULTIEPITOPE POLYPEPTIDES IN IMPROVED SEASONAL AND PANDEMIC INFLUENZA VACCINESDecember 2013January 2016Allow2921NoNo
14138991HCV CORE LIPID BINDING DOMAIN MONOCLONAL ANTIBODIESDecember 2013February 2016Allow2611NoNo
14127052EPITOPE AND ITS USE OF HEPATITIS B VIRUS SURFACE ANTIGENDecember 2013May 2016Allow2921NoNo
14073488HCV GENOTYPE 6 REPLICONSNovember 2013January 2016Allow3621YesNo
13641560AGENT FOR USE IN THE TOPICAL OR LOCAL TREATMENT OF CERVICAL DYSPLASIASOctober 2012March 2014Allow1721YesNo
13553137PEPTIDES SHARED AMONG LETHAL CANCERS AND THERAPEUTIC COMPOSITIONS COMPRISING SAID PEPTIDESJuly 2012December 2015Allow4121YesNo
13540421RECOMBINANT ADENOVIRUSES ENCODING THE SPECIFIC IODINE TRANSPORTER (NIS)July 2012October 2013Allow1510NoNo
13532425VACCINES CONTAINING CANINE PARVOVIRUS GENETIC VARIANTSJune 2012August 2013Allow1311NoNo
13528407HUMANIZED ANTI-CCR2 ANTIBODIES AND METHODS OF USE THEREFORJune 2012May 2014Allow2311NoNo
13511116HEPATITUS B VIRUS SPECIFIC ANTIBODY AND USESE THEREOFMay 2012January 2016Allow4431NoNo
13499488ADJUVANTED VACCINE FORMULATIONSMay 2012May 2017Allow6051YesNo
13462314VACCINE FOR MODULATING BETWEEN T1 AND T2 IMMUNE RESPONSESMay 2012May 2013Allow1310NoNo
13364952MINIMAL MOTIFS OF LINEAR B-CELL EPITOPES IN L1 PROTEIN FROM HUMAN PAPILLOMAVIRUS TYPE 58 AND THEIR APPLICATIONSFebruary 2012February 2014Allow2411NoNo
13254039METHODS FOR PROLIFERATION OF ANTIGEN-SPECIFIC T CELLSJanuary 2012April 2015Allow4421YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BOESEN, AGNIESZKA.

Strategic Value of Filing an Appeal

Total Appeal Filings
14
Allowed After Appeal Filing
3
(21.4%)
Not Allowed After Appeal Filing
11
(78.6%)
Filing Benefit Percentile
25.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 21.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner BOESEN, AGNIESZKA - Prosecution Strategy Guide

Executive Summary

Examiner BOESEN, AGNIESZKA works in Art Unit 1671 and has examined 179 patent applications in our dataset. With an allowance rate of 92.2%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.

Allowance Patterns

Examiner BOESEN, AGNIESZKA's allowance rate of 92.2% places them in the 77% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BOESEN, AGNIESZKA receive 2.39 office actions before reaching final disposition. This places the examiner in the 82% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BOESEN, AGNIESZKA is 39 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +5.8% benefit to allowance rate for applications examined by BOESEN, AGNIESZKA. This interview benefit is in the 32% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 31.7% of applications are subsequently allowed. This success rate is in the 58% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 46.3% of cases where such amendments are filed. This entry rate is in the 65% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 76.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 69.0% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 16.2% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.